New study reveals the extent to which drugmakers use condition-specific charities to induce spending on costly drugs
It’s well known that pharma companies are interested in and often help patients pay for typically unaffordable drugs, often via drugmaker-funded charities and often at odds with the regulations.
But what a new study in Health Affairs uncovers is just how pervasive this practice has become, with the Harvard-, Northwestern- and USC-affiliated authors noting the “substantial and growing” reach of patient assistance charities from 2010 to 2017.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
